ReviewTherapeutic advances in hematology2019

Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia.

Matteo Molica et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.